IceCure Reports Q1 2026 Earnings with Strong Revenue and Sales Growth
IceCure (ICCM) reported a 26% year-over-year revenue growth in the first quarter of 2026, driven by new system placements and increased disposable probe sales. North America saw an 84% increase in sales for Q1, with U.S. revenue rising 31%. The company also noted significant expansion in active accounts and international interest following FDA clearance.
